InformationEmricasan (IDN-6556) Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.In vitroEmricasan, also called IDN-6556 or PF-03491390, is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan shows neuroprotective activity for hNPCs but does not suppress ZIKV replication.In vivoEmricasan decreases liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of the pan-caspase inhibitor Emricasan. Emricasan is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection.Cell Datacell lines:Concentrations:9 μMIncubation Time:1 hPowder Purity:≥98%.
Specifications and Purity: 10mM in DMSO
Molecular Formula: C26H27F4N3O7
Molecular Weight: 569.5
- UPC:
- 42181516
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- E409139-1ml
- CAS:
- 254750-02-2
- Product Size:
- 1ml
akash.verma@cenmed.com
(732) 447-1115





